



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

BI-671800

Cat. No.: HY-114141
CAS No.: 1093108-50-9
Molecular Formula: C₂₅H₂₆F₃N₅O₃
Molecular Weight: 501.5
Target: Prostaglandin Receptor
Pathway: GPCR/G Protein
Storage: 4°C, protect from light
 * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 135 mg/mL (269.19 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		1.9940 mL	9.9701 mL	19.9402 mL
		5 mM		0.3988 mL	1.9940 mL	3.9880 mL
		10 mM		0.1994 mL	0.9970 mL	1.9940 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.25 mg/mL (4.49 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.25 mg/mL (4.49 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	BI-671800 is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2), with IC ₅₀ values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively ^[1] . BI-671800 has potential for the treatment of poorly controlled asthma ^[2] .	
IC ₅₀ & Target	hCRTH2 4.5 nM (IC ₅₀)	mCRTH2 3.7 μM (IC ₅₀)
In Vitro	BI-671800 (compound A) exhibits low nM potency as an antagonist of human or mouse CRTH2 in transfected cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	BI-671800 (compound A, 0.1-10 mg/kg, i.g.) shows significant inhibition of AHR in mice ^[1] .	

BI-671800 (compound A), effectively blocks edema formation and greatly reduces the inflammatory infiltrate and skin pathology observed in drug vehicle-treated animals^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8-week-old age- and sex-matched BALB/c mice (mice were sensitized for 14 days, challenged intranasally) ^[1] .
Dosage:	10-0.1 mg/kg
Administration:	Oral gavage for 4 weeks
Result:	Shows significant inhibition of AHR in mice.

REFERENCES

- [1]. Boehme SA, et al. A small molecule CRTH2 antagonist inhibits FITC-induced allergic cutaneous inflammation. *Int Immunol*. 2009 Jan;21(1):81-93.
- [2]. Miller D, et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. *Allergy Asthma Proc*. 2017 Mar 1;38(2):157-164.
- [3]. Lukacs NW, et al. CRTH2 antagonism significantly ameliorates airway hyperreactivity and downregulates inflammation-induced genes in a mouse model of airway inflammation. *Am J Physiol Lung Cell Mol Physiol*. 2008 Nov;295(5):L767-79.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA